Table 1.
Clinicopathological features of nulliparous and parous patients
| N | Nulliparous | Parous | P | Early parous | Late parous | P |
|---|---|---|---|---|---|---|
| 49 | 264 | 82 | 71 | |||
| Age at diagnosis | 54 (30–81) | 55 (28–81) | 0.796a | 59 (34–81) | 49 (28–81) | 2.6 × 10–5a |
| Menopausal status | ||||||
| Pre | 13 (33.3%) | 60 (30.3%) | 0.85 | 14 (20.9%) | 29 (45.3%) | 0.0053 |
| Post | 26 (66.7%) | 138 (69.7%) | 53 (79.1%) | 35 (54.7%) | ||
| Stage | ||||||
| I | 7 (14.9%) | 41 (15.9%) | 0.019 | 6 (7.6%) | 17 (24.3%) | 0.039 |
| II | 20 (42.6%) | 81 (31.4%) | 33 (41.8%) | 27 (38.6%) | ||
| III | 11 (23.4%) | 30 (11.6%) | 12 (15.2%) | 10 (14.3%) | ||
| IV | 0 (0%) | 1 (0.4%) | 1 (1.3%) | 0 (0%) | ||
| Na | 9 (19.1%) | 105 (40.7%) | 27 (34.2%) | 16 (22.9%) | ||
| pT | ||||||
| Tx | 9 (18.4%) | 105 (39.8%) | 0.0062 | 27 (32.9%) | 16 (22.5%) | 0.012 |
| ≤ 2 cm | 11 (22.4%) | 61 (23.1%) | 13 (15.9%) | 26 (36.6%) | ||
| > 2 cm | 29 (59.2%) | 98 (37.1%) | 42 (51.2%) | 29 (40.8%) | ||
| pN | ||||||
| Nx | 11 (22.4%) | 112 (42.4%) | 0.027 | 30 (36.6%) | 17 (23.9%) | 0.2 |
| N0 | 18 (36.7%) | 79 (29.9%) | 25 (30.5%) | 23 (32.4%) | ||
| N1+ | 20 (40.8%) | 73 (27.7%) | 27 (32.9%) | 31 (43.7%) | ||
| Grade | ||||||
| I | 6 (14%) | 29 (12.7%) | 0.93 | 8 (9.8%) | 5 (7%) | 0.059 |
| II | 17 (39.5%) | 86 (37.7%) | 25 (30.5%) | 35 (49.3%) | ||
| III | 20 (46.5%) | 113 (49.6%) | 49 (59.8%) | 31 (43.7%) | ||
| Subtype by IHC | ||||||
| Lum A-like | 22 (44.9%) | 106 (40.3%) | 0.0013 | 29 (35.4%) | 39 (54.9%) | 0.026 |
| Lum B-like | 19 (38.8%) | 54 (20.5%) | 20 (24.4%) | 17 (23.9%) | ||
| HER2+/HR+ | 6 (12.2%) | 29 (11%) | 0 (0%) | 0 (0%) | ||
| HER2+/HR- | 0 (0%) | 13 (4.9%) | 1 (1.2%) | 1 (1.4%) | ||
| TNBC | 2 (4.1%) | 61 (23.2%) | 32 (39%) | 14 (19.7%) | ||
| Histology | ||||||
| Ductal | 36 (76.6%) | 203 (81.2%) | 0.67 | 71 (88.8%) | 49 (71%) | 0.01 |
| Lobular | 5 (10.6%) | 23 (9.2%) | 2 (2.5%) | 10 (14.5%) | ||
| Other | 6 (12.8%) | 24 (9.6%) | 7 (8.8%) | 10 (14.5%) | ||
pT pathological tumor size, pN pathological nodal status, HR hormone receptor, P P value derived from χ2 test or the Fisher exact test when appropriate
aExcept continuous variable derived from Mann–Whitney U test